207923-07-7

Basic information

• Product Name: Phenol, 5-amino-2-ethyl-
• CAS NO: 207923-07-7
• Molecular Formula: C8H11NO
• Molecular Weight: 137.181
• Mol File: 207923-07-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Phenol, 5-amino-2-ethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 5-amino-2-ethyl-(207923-07-7)
• EPA Substance Registry System: Phenol, 5-amino-2-ethyl-(207923-07-7)

Safety Data

• Hazardous Substances Data: 207923-07-7(Hazardous Substances Data)

Upstream product

• 2896-60-8 4-ethyl-1,3-benzenediol 
• 2476-29-1 4-amino-2-hydroxy-acetophenone 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 20191-74-6 2-ethyl-5-nitroaniline 
• 578-54-1 ortho-ethylaniline 
• 214896-18-1 5-nitro-2-vinylphenol 
• 52427-05-1 2-bromo-5-nitrophenol 
• 90005-90-6 2-ethyl-5-nitro-phenol 

Downstream Products

• 860508-06-1 3-ethyl-6-amino-2-hydroxy-benzoic acid 
• 933045-59-1 2-ethyl-5-(thiazol-2-ylamino)phenol 

Relevant articles and documents

Selective hydrodeoxygenation of acetophenone derivatives using a Fe25Ru75@SILP catalyst: a practical approach to the synthesis of alkyl phenols and anilines

A versatile synthetic pathway for the production of valuable alkyl phenols and anilines has been developed based on the selective hydrodeoxygenation of a wide range of hydroxy-, amino-, and nitro-acetophenone derivatives as readily available substrates. Bimetallic iron ruthenium nanoparticles immobilized on an imidazolium-based supported ionic liquid phase (Fe25Ru75@SILP) act as highly active and selective catalysts for the deoxygenation of the side-chain without hydrogenation of the aromatic ring. The catalytic system allows operation under continuous flow conditions with high robustness and flexibility as demonstrated for the alternating conversion of 3′,5′-dimethoxy-4′-hydroxyacetophenone and 4′-hydroxynonanophenone as model substrates.

COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER

The present invention relates to compounds according to the formula I: Where Ra is H or an optionally OH-substituted C1-C3 alkyl; R1 is OR1, an optionally substituted C4-12 carbocyclic group which may be saturated or unsaturated (including aromatic) or an optionally substituted heterocyclic group; R1 is an optionally substituted C1-C14 hydrocarbyl group or an optionally substituted heterocyclic group;; R2 , R3 and R4 are each independently H, an optionally substituted C1-C4 alkyl group (preferably CH3, CH2CH3 or CF3), halogen (preferably F, Cl, Br), OR, CN, NO2, a C1-C6 thioether, a C1-C6 thioester group, an optionally substituted CO2R group, an optionally substituted COR group or an optionally substituted OCOR group (preferably R4 is H); R is H or an optionally substituted C1-C6 alkyl group; RHET is an optionally substituted heterocyclic group; and pharmaceutically acceptable salts, solvates or polymorphs thereof.